Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 8/20 | 0.79 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | EBP | Q15125 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491598 | 0.92 | KCNH2 (0.68) | KCNH2ATML3MBTL1ALDH1A1PTGS2 | |
| Hydrochloric Acid SCHEMBL10425864 | 0.91 | KCNH2 (0.67) | KCNH2ATML3MBTL1ALDH1A1PTGS2 | |
| SCHEMBL11063943 | 0.86 | KCNH2 (0.65) | KCNH2L3MBTL1ALDH1A1MAPT | |
| SCHEMBL5282391 | 0.83 | KCNH2 (0.58) | KCNH2ATML3MBTL1ALDH1A1MAPT | |
| SCHEMBL1962562 | 0.83 | KCNH2 (0.68) | KCNH2LTA4HPTGS2MAPTGAA | |
| SCHEMBL28751537 | 0.83 | KCNH2 (0.61) | KCNH2L3MBTL1ALDH1A1PTGS2MAPT | |
| SCHEMBL10511052 | 0.83 | KCNH2 (0.67) | KCNH2L3MBTL1MAPT | |
| SCHEMBL4933227 | 0.83 | KCNH2 (0.63) | KCNH2ALDH1A1LTA4HPTGS2MAPT | |
| SCHEMBL9706125 | 0.82 | EBP (0.72) | KCNH2EBPSIGMAR1CYP1A2LTA4H | |
| Hydrochloric Acid SCHEMBL3570004 | 0.82 | KCNH2 (0.67) | KCNH2LTA4HMAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2026-05-12 | — | — | US | disclosed |
| US-12516055-B2 | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | TRUSTEES OF TUFTS COLLEGE (US) | 2026-01-06 | — | — | US | disclosed |
| CN-119707835-A | 2-Aminopyrimidine-5-carboxamide compounds and use thereof for the production of medicaments for the treatment and/or prophylaxis of cancer | 沈阳药科大学 | 2025-03-28 | — | — | CN | disclosed |
| EP-4480485-A2 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | University of Houston System (US) | 2024-12-25 | — | — | EP | disclosed |
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-10-03 | — | — | US | disclosed |
| EP-3968991-B1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIV HOUSTON SYSTEM (US) | 2024-07-31 | — | — | EP | disclosed |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2024-06-18 | — | — | US | disclosed |
| WO-2024097805-A1 | MIXED LINEAGE KINASE DOMAIN LIKE PSEUDOKINASE (MLKL) ACTIVATORS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024097805-A1 | MIXED LINEAGE KINASE DOMAIN LIKE PSEUDOKINASE (MLKL) ACTIVATORS | TRUSTEES OF TUFTS COLLEGE (US) | 2024-05-10 | — | — | WO | disclosed |
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | UNIVERSITY OF HOUSTON SYSTEM | 2022-06-23 | — | — | US | disclosed |
| US-6150373-A | AMINO-SUBSTITUTED DIHYDROPYRIMIDO(4,5-D)PYRIMIDINONE DERIVATIVES; INHIBITORS OF THE T-CELL TYROSINE KINASE P56LCK; IMMUNOSUPPRESSANTS; ANTIINFLAMMATORY/-CARCINOGENIC AGENTS; BRONCHOPULMONARY, DERMATOLOGICAL AND CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| WO-2000024744-A1 | BICYCLIC NITROGEN HETEROCYCLES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-05-04 | — | — | WO | disclosed |
| EP-0618916-B1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | KNOLL AG (DE) | 1998-09-23 | — | — | EP | disclosed |
| US-5464781-A | TREATING RHEUMATIC DISEASES | THE BOOTS COMPANY PLC (GB) | 1995-11-07 | — | — | US | disclosed |
| WO-1993013097-A1 | ANTI-RHEUMATIC NAPHTHYRIDINE DERIVATIVES | THE BOOTS COMPANY PLC (GB) | 1993-07-08 | — | — | WO | disclosed |
| EP-0138302-B1 | PYRAZOLO(3,4,5-KL)ACRIDINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND PROCESSES FOR THEIR PRODUCTION | WARNER-LAMBERT COMPANY (US) | 1988-03-09 | — | — | EP | disclosed |
| US-4621086-A | Method of treating leukemia with pyrazolo[3,4,5-kl]acridines | WARNER-LAMBERT COMPANY (US) | 1986-11-04 | — | — | US | disclosed |
| US-4588730-A | Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials | WARNER-LAMBERT COMPANY (US) | 1986-05-13 | — | — | US | disclosed |
| US-4555572-A | Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use | WARNER-LAMBERT COMPANY (US) | 1985-11-26 | — | — | US | disclosed |
| EP-0138302-A1 | Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production | WARNER-LAMBERT COMPANY (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327403-A1 | PYRIDO[2,3-d]PYRIMIDIN-7-ONES AND RELATED COMPOUNDS AS INHIBITORS OF PROTEIN KINASES | RIPK2, RIPK1, RIPK4 | KCNH2 2419/4885ATM 860/4885L3MBTL1 2339/4885 |
| US-12012402-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | KCNH2 2419/4885ATM 860/4885L3MBTL1 2339/4885 |
| US-20220194937-A1 | PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS | RIPK2, RIPK1, RIPK4 | KCNH2 4339/4885ATM 559/4885L3MBTL1 1581/4885 |
| US-12624032-B2 | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | RIPK2, RIPK1, RIPK4 | KCNH2 1648/4885ATM 429/4885L3MBTL1 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.